As of 12:30 PM on the 3rd, SK is trading at 272,500 KRW, down 2.15% from the previous day. The trading volume is 798,038 shares, which is about 27.89% of the previous day's volume. SK is known as the holding company of the SK Group.

On July 2nd, Yang Il-woo, a researcher at Samsung Securities, stated, "We expect SK's stock price to rise because the holding company's market capitalization is anticipated to reflect the increase in NAV with high elasticity. The reasons are: 1) SK Pharmteco, a CMO company and a 100% subsidiary of SK, is expected to benefit from the improved performance of SK Biopharm; 2) SK Biopharm's strong performance is seen as an opportunity to anticipate future CMO investments in biopharmaceuticals by SK; 3) Although small in scale, synergies are expected between other bio companies invested in by SK, such as Standigm, and SK Biopharm." He set the target price for SK at 388,000 KRW.

Over the past five days, individual investors have net purchased 478,588 shares of SK, while foreigners and institutions have net sold 690,623 shares and net purchased 195,318 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.




This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing